Health
Novo Nordisk A/S: More efficacious dose of Wegovy® recommended by the European Medicines Agency can help people with obesity achieve an average of 20.7% weight loss
The European Medicines Agency (EMA) has issued a positive opinion for a new Wegovy® 7.2 mg dose, advancing its availability in the European Union (EU)In the STEP UP programme, people with obesity taking Wegovy® 7.2 mg lost an average of 20.7% body weight at 72 weeks; one in three people achieved 25% or more weight loss1*The higher dose adds a new option for substantial weight loss while preserving muscle function and maintaining the established cardiovascular health benefits of Wegovy®2 Bagsværd
About this update from Novo Nordisk A/s Class B
[{"type":"image","alt":"Novo Nordisk A/S","displaySize":"","headline":null,"caption":"Novo Nordisk A/S","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":214,"url":"https://media.zenfs.com/en/globenewswire.com/b199128d4b2bbea4504ed4a2f3b29b4e"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Sq36MpNFOiz.w6RiXrpsqg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTMwMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/b199128d4b2bbea4504ed4a2f3b29b4e","width":300,"height":214}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"The European Medicines Agency (EMA) has issued a positive opinion for a new Wegovy® 7.2 mg dose, advancing its availability in the European Union (EU)","length":150,"tagName":"p"}]},{"val":[{"type":"text","content":"In the STEP UP programme, people with obesity taking Wegovy® 7.2 mg lost an average of 20.7% body weight at 72 weeks; one in three people achieved 25% or more weight loss1*","length":172,"tagName":"p"}]},{"val":[{"type":"text","content":"The higher dose adds a new option for substantial weight loss while preserving muscle function and maintaining the established cardiovascular health benefits of Wegovy®2","length":169,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":491,"olType":false},{"type":"text","content":"Bagsværd, Denmark, 12 December 2025 – Today, the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion for a higher dose of Wegovy® (semaglutide 7.2 mg), bringing it a step closer to offering individuals with obesity in the EU a new Wegovy® option for even greater weight loss. The new dose of Wegovy® has demonstrated an average weight loss of 20.7% at 72 weeks, in people with obesity who do not have diabetes.1* These substantial weight loss results complement the already established health benefits of Wegovy® in obesity-related complications, including significant reduction in the risk of cardiovascular events such as heart attack and stroke, and reduction in pain from knee osteoarthritis.2,3","length":761,"tagName":"p"},{"type":"text","content":"The positive opinion is based on the results from the STEP UP and STEP UP T2D clinical trial programme in people with obesity with and without type 2 diabetes.1,4 In people with obesity and without diabetes, one in three participants treated with Wego...